Scientists of the Competence Center of National Technological Initiative (NTI according to Russian abbreviation) are developing a drug based on a fragment of the human protein Lynx1, which recovers the memory of the patients with Alzheimer’s disease and dementia. This Competence Center was established on the basis of M. M. Shemyakin y Yu. A. Ovchinnikov Bioorganic Chemistry Institute of the Russian Academy of Sciences (IBKH according to Russian abbreviation). The news item was reported by Zakhar Shenykarev, the head of the laboratory of bioengineering of antitumoural drugs and artificial neuromodulators of the center.
Scientists from the NTI Competence Center have found that protein Lynx1, which is responsible for the capacity of the brain to restore lost or damaged connections, prevents the interaction of amylides with nicotine receptors. As part of the drug, Lynx1 could “protect” these receptors, slowing down the development of the disease and even returning memory to patients; believe the authors of the study.
“With the help of protein Lynx1, it is possible to slow down the development of Alzheimer’s disease and to recover such lost functions as memory. At the same time, only a part of a protein – a small peptide – is enough to get the effect, which significantly reduces the cost of the drug production,” said Schenkarev.
The authors of the study tested samples of the drug with a fragment of protein Lynx1 on mice. As a consequence of the systematic introduction of the drug into animals’ organism, their memory was restored. In case of motor memory, sick animals restored their ability to hold on the rotating drum. The authors of the research plan to complete the animal testing by the end of 2020.